GLP-1 for PCOS: Semaglutide and Tirzepatide Evidence

PCOS and weight gain is not a discipline problem

This is your first and most important thing to know: weight gain tied to PCOS is not a character flaw. It is not a failure of willpower or effort. It is a metabolic condition. Your body is not working against you because you are undisciplined. Insulin resistance, which is common in PCOS, changes how your cells process energy and store fat.

That distinction matters because the standard weight loss advice, such as eating less and moving more, does not account for the underlying biology. You can follow that advice perfectly and still struggle with weight. The 2023 international PCOS guideline now lists GLP-1 medications as an option a provider could consider, alongside lifestyle changes, for managing higher weight in adults with PCOS^[2].

What PCOS actually is and why weight loss feels impossible

Polycystic ovary syndrome is usually diagnosed when at least two of three features are present: androgen excess (higher levels or effects of male hormones), irregular or absent ovulation, and polycystic ovaries^[1]. Insulin resistance is not one of the diagnostic criteria, but the 2023 international guideline describes it as a key feature of PCOS^[2].

Here is what happens. Your cells do not respond properly to insulin, so your pancreas produces more and more insulin to try to push glucose into them. All that extra insulin encourages your body to store fat. It also stimulates your ovaries to produce more androgens, which further disrupts your menstrual cycle and metabolism.

This is why the “eat less, move more” advice rings hollow. You are not struggling simply because you are eating too much or moving too little. Excess insulin can make weight loss harder and fat storage easier.

Many women with PCOS have been told their weight is the cause of their symptoms. The relationship runs both ways: insulin resistance can drive weight gain, and weight gain can worsen insulin resistance. That is why addressing insulin resistance is part of the picture.

How GLP-1 medications interact with PCOS

GLP-1 medications work on several mechanisms that are relevant to PCOS. Understanding this helps explain why researchers are interested in their use for this population.

GLP-1 medications can lower insulin resistance. In a meta-analysis of randomized trials in women with PCOS, GLP-1 medications reduced fasting insulin and HOMA-IR, a common measure of insulin resistance^[4].

Lower insulin could, in theory, lower androgen production. Because insulin stimulates the ovaries to make androgens, lowering insulin could reduce androgen levels. So far, though, meta-analyses of PCOS trials have not shown clear changes in testosterone or other hormone levels, and evidence on hirsutism (excess hair growth) and menstrual regularity is insufficient to draw conclusions^[3][4].

Weight loss itself can help. When you lose weight, insulin sensitivity often improves further. The two effects can reinforce each other, though how much varies from person to person.

The 2023 international PCOS guideline, supported by partners including the Endocrine Society, says anti-obesity medications, including GLP-1 medications such as liraglutide and semaglutide, could be considered in addition to lifestyle changes for managing higher weight in adults with PCOS, in line with general population guidelines^[2].

What the research actually shows

The evidence base for GLP-1 use in PCOS is growing, but it is important to be clear about what we know and do not know.

A 2026 systematic review found 11 randomized controlled trials of GLP-1 medications in women with PCOS. GLP-1 medications added to other treatment were associated with modest short-term weight loss (an average BMI reduction of about 1.4 points compared with control groups). The certainty of that evidence was low, and evidence on glucose, insulin, hirsutism, and menstrual regularity was insufficient to draw conclusions^[3]. A 2025 meta-analysis of randomized trials reported reductions in weight, BMI, waist size, and insulin resistance, no clear change in hormone levels, and more nausea, vomiting, and dizziness with GLP-1 medications^[4].

Large, long-term randomized trials conducted specifically in PCOS populations are still lacking. Most PCOS trials to date have been small and short, and many used older GLP-1 medications such as liraglutide or exenatide. This is not unusual for newer uses of medications, but it means the evidence is still developing. Results vary.

What matters for your decision: GLP-1 medications are not FDA-approved for PCOS treatment. Use for PCOS itself is off-label, which means a licensed provider is making a clinical judgment that the medication is appropriate for your specific situation based on published evidence and your health history. Off-label prescribing is legal and common in medicine, but the decision is individualized.

Menstrual regularity and androgen levels

One of the questions many women with PCOS ask is whether GLP-1 medications can improve menstrual regularity or hormone levels. The honest answer is that the research has not settled it.

Weight loss may improve menstrual regularity for some women with PCOS, although the 2013 Endocrine Society guideline described the role of weight loss in improving PCOS itself as uncertain^[1]. In trials of GLP-1 medications in PCOS, evidence on menstrual regularity was insufficient to draw conclusions^[3].

Androgen levels have not shown clear changes in meta-analyses of these trials^[4]. Some women report clearer skin or less excess hair growth as they lose weight, but that has not been established in the trial data.

These outcomes are not guaranteed. Hormonal response varies significantly from person to person. A licensed provider can help you understand what realistic changes might look like for your situation based on your labs and symptoms.

GLP-1 Medications and Pregnancy Planning

This section is critical if you are of reproductive age or planning pregnancy. Here is what you need to know.

Why GLP-1 medications must be stopped before pregnancy

GLP-1 medications are not used during pregnancy, and both labels below warn of possible fetal harm based on animal studies. Human pregnancy data are limited. The labels differ on timing:

• Wegovy (semaglutide): the label says to stop at least 2 months before a planned pregnancy because of semaglutide’s long half-life, and to stop when a pregnancy is recognized^[5].
• Zepbound (tirzepatide): the label says to stop when a pregnancy is recognized. It does not list a specific washout period before a planned pregnancy^[6].

Because these medications stay in your body for a while after the last dose, stopping on the day you start trying is not the same as planning ahead. Ask your prescriber about the right timing for the medication you take.

The fertility paradox: PCOS, conception, and GLP-1

Here is where things get complex. For some women with PCOS, losing weight can bring back ovulation and more regular cycles. That can make pregnancy possible, even though GLP-1 medications are not used during pregnancy.

For women with PCOS:

• Weight loss and lower insulin resistance may allow ovulation to resume in some women
• Ovulation may return before periods become fully regular
• This means pregnancy risk can rise after starting treatment, even if your cycles were previously absent or highly irregular

If you are not trying to conceive: Use effective contraception while taking GLP-1 medications. The 2023 international PCOS guideline advises effective contraception when pregnancy is possible for women taking GLP-1 medications, because pregnancy safety data are lacking^[2].

If you are trying to conceive: Work closely with your prescriber, and with a fertility specialist if you have one, to plan the timing. The 2023 international guideline recommends using anti-obesity medications for fertility outcomes only in research settings, until their effectiveness and safety for that purpose are established^[2]. If you do use a GLP-1 medication for weight before trying to conceive, plan the stop date ahead of time (at least 2 months before a planned pregnancy for Wegovy, per its label^[5]).

Oral contraceptive interactions

If you take birth control pills and use tirzepatide (the GIP/GLP-1 receptor agonist in Zepbound and Mounjaro), the Zepbound label warns that tirzepatide may make oral hormonal contraceptives less effective because it slows stomach emptying. The effect is largest after the first dose and lessens over time. In a study described on the label, a single 5 mg dose of tirzepatide lowered overall exposure to the pill’s hormones by about 20 percent^[6].

What the label says: switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. Hormonal contraceptives that are not taken by mouth should not be affected^[6]. The Wegovy label does not include this instruction, and it lists no clinically significant change in ethinyl estradiol or levonorgestrel levels with semaglutide^[5]. Confirm your own birth control plan with your prescriber.

Fertility treatment considerations

Some women with PCOS consider using GLP-1 medications to lose weight before pursuing fertility treatments or trying to conceive. Because the 2023 international guideline recommends this for fertility outcomes only in research settings^[2], it requires careful, coordinated planning:

1. Baseline fertility evaluation (ovulation testing, partner evaluation if applicable)
2. A clear plan for how long any GLP-1 treatment will last, set with your prescriber
3. A medication-free period before attempting conception or starting fertility treatments, timed to the label for your medication
4. Ongoing coordination between your GLP-1 prescriber and your fertility specialist

For more information on this topic, see our detailed guide on GLP-1 and Fertility.

Who tends to benefit most

Not every person with PCOS will benefit from GLP-1 medications, and not every person will be a candidate. A licensed provider will weigh several factors.

FDA-approved GLP-1 weight-management medications are indicated for adults with obesity, or overweight with at least one weight-related condition. In practice that generally means a BMI of 30 or higher, or 27 or higher with a condition like prediabetes or high blood pressure. This is the population that has been studied most, and the 2023 international guideline frames GLP-1 use in PCOS around managing higher weight^[2].

Insulin resistance matters too. If you have prediabetes or other signs of insulin resistance alongside PCOS, the clinical case for treatment may be stronger. The guideline notes that routine insulin blood tests are of limited clinical value, so a single insulin test is usually not the deciding factor^[2].

If you have already tried metformin for PCOS without sufficient improvement, GLP-1 medications have a different mechanism and may provide additional benefit when used alongside or instead of metformin. These are clinical decisions a licensed provider makes based on your specific history.

It is also important to be realistic about what you are treating. If your PCOS diagnosis is based primarily on ultrasound findings or irregular cycles but without significant weight concerns or metabolic dysfunction, GLP-1 medications may not be appropriate. A licensed provider can help you decide.

How the process should work

At most telehealth programs, a licensed provider reviews your health history, including your PCOS diagnosis, your current symptoms, your labs (if available), and your goals, and decides whether a prescription is appropriate.

That is a medical decision, not an automatic approval. Some people with PCOS will not be candidates. Some may need to address other health factors first. If you are comparing programs, ask:

• Will the prescriber ask about pregnancy plans and birth control? A careful intake should cover both, given the label instructions above.
• Are labs included or billed separately? Some programs include baseline labs; others bill separately or ask you to get them through your own provider.
• How are dose increases handled? Ask how often the prescriber checks in during escalation and what happens if side effects make it hard to move to the next dose.
• Will they coordinate with your other providers? That includes your gynecologist, endocrinologist, or fertility specialist.

Talk about how long you might stay on medication. The 2023 international guideline notes that GLP-1 use for weight may need to be long-term, because weight regain after stopping is common, and long-term safety data in PCOS are lacking^[2].

Transformation Health does not accept payment from providers. How we make money.

What to check before using a GLP-1 medication

Programs differ in what they prescribe and what they charge. A few things to confirm:

• Brand-name or compounded? Some programs prescribe FDA-approved brand-name medications such as Wegovy (semaglutide) or Zepbound (tirzepatide). Others prescribe compounded semaglutide or tirzepatide, prepared by state-licensed compounding pharmacies. Compounded semaglutide and tirzepatide are not FDA-approved and are not the same as brand-name products such as Wegovy or Zepbound. The FDA does not review them for safety, effectiveness, or quality, and they may differ in formulation, purity, and potency.
• Does the trial evidence apply? Clinical trial data on safety and effectiveness apply to the brand-name products studied in those trials, not to compounded versions.
• What is the total cost? Prices vary by program and dose. Compare the total cost: medication, dose increases, visits, labs, shipping, membership fees, and cancellation terms.
• Which medication, dose, and form? A licensed provider decides which medication and dose, if any, is appropriate for you.

How to get started

For background on how prescribing works, see How getting a GLP-1 prescription works and the GLP-1 Eligibility Guide, which explains the usual qualification criteria.

For a detailed comparison of semaglutide and tirzepatide, including how they differ for specific situations, see Semaglutide vs Tirzepatide.

Citations

[1] Legro RS, et al. “Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline.” Journal of Clinical Endocrinology and Metabolism 2013;98(12):4565-4592. https://pubmed.ncbi.nlm.nih.gov/24151290/ (Rotterdam diagnostic criteria; role of weight loss in improving PCOS itself described as uncertain.)

[2] Teede HJ, et al. “Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome.” Journal of Clinical Endocrinology and Metabolism 2023;108(10):2447-2469. https://pubmed.ncbi.nlm.nih.gov/37580314/ (Recommendations 4.5.1-4.5.4 on GLP-1 medications for higher weight, contraception, and long-term use; 5.9.1 on fertility outcomes; 1.9.12 on insulin resistance.)

[3] Forslund M, et al. “GLP-1 receptor agonist treatment in women with polycystic ovary syndrome: a systematic review and meta-analysis.” European Journal of Endocrinology 2026;194(3):25-39. https://pubmed.ncbi.nlm.nih.gov/41701618/ (11 randomized trials; modest short-term weight loss, low certainty; insufficient evidence on insulin, hirsutism, and menstrual regularity.)

[4] Lin S, et al. “Efficacy and safety of GLP-1 receptor agonists on weight management and metabolic parameters in PCOS women: a meta-analysis of randomized controlled trials.” Scientific Reports 2025;15(1):16512. https://pubmed.ncbi.nlm.nih.gov/40360648/ (Reductions in weight, BMI, and insulin resistance; hormone levels unchanged; more nausea, vomiting, and dizziness.)

[5] Novo Nordisk. Wegovy (semaglutide) prescribing information. US Food and Drug Administration. Revised 06/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf (Sections 8.1 and 8.3: stop at least 2 months before a planned pregnancy; section 12.3: no clinically significant change in ethinyl estradiol or levonorgestrel.)

[6] Eli Lilly and Company. Zepbound (tirzepatide) prescribing information. US Food and Drug Administration. Revised 08/2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf (Sections 8.1 and 8.3: stop when pregnancy is recognized; oral hormonal contraceptive instructions; section 12.3: contraceptive interaction study.)